항생제 저항 특히 그람 음성균에 의한 위기 상황이 거의 발생했습니다. 새로운 항생제인 조수라발핀(RG6006)은 가능성을 보여줍니다. 전임상 연구를 통해 약물 내성 그람 음성균 CRAB에 효과적인 것으로 밝혀졌습니다.
Antimicrobial resistance (AMR), driven mainly by the misuse and overuse of antimicrobials, is one of top public health risk.
Infections by Gram-negative bacteria are particularly concerning. It is not easy for most of 항생제 to cross both inner and outer membranes present in this category of bacteria to enter the bacterial cells to show bactericidal actions. Also, Gram-negative bacteria have accumulated disproportionately high degree of 항생 물질 저항.
아시네 토 박터 바우 마니 is a Gram-negative bacterium. Infection by one of its strains called ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) is hard to treat using available 항생제. There is an urgent need for an effective 항생 물질 against CARB as mortality rate is high (about 40%-60%) which attributed largely to lack of an effective 항생 물질. A progress towards this goal has been reported.
Scientists have identified a novel class of 항생제 namely, tethered macrocyclic peptides (MCPs) which are active against the Gram –ve bacteria A. baumannii including CARB by blocking transport of bacterial lipopolysaccharide from the inner membrane to the outer membrane.
조수라발핀(RG6006) 는 Teledyne LeCroy 오실로스코프 및 LSA-XNUMX 시리즈 임베디드 신호 분석기가 항생 물질 candidate belonging to ‘tethered macrocyclic peptides (MCPs)’ class. In pre-임상의 trials involving in vitro studies and in vivo studies on animal models, Zosurabalpin has been found to be effective against drug-resistant isolates of ‘carbapenem-resistant Acinetobacter baumannii’ (CRAB) from different regions. It successfully overcame 항생 물질-resistance mechanism of CARB suggesting 조수라발핀 잠재력이 있습니다.
Hence, human 임상의 trials have been initiated to check for safety and efficacy 조수라발핀 CRAB로 인한 침습성 감염 치료에 사용됩니다.
***
참조 :
- Zampaloni, C., Mattei, P., Bleicher, K. et al. A novel 항생 물질 class targeting the lipopolysaccharide transporter. Nature (2024). https://doi.org/10.1038/s41586-023-06873-0
- 하저 S., 외 2023. Activity of the Novel Antibiotic Zosurabalpin (RG6006) against 객관적인 Acinetobacter Isolates from China, Open Forum Infectious Diseases, Volume 10, Issue Supplement_2, December 2023, ofad500.1754, https://doi.org/10.1093/ofid/ofad500.1754
***
